In a conclusion, our data indicate that the shorter kidney disease history, lower serum level of β2‐microglobulin and free light chain, achieving at least VGPR is related to a high probability of hemodialysis discontinuation and bortezomib‐based regimens were strongly recommended for treatment of MM patients requiring dialysis. The gene discussed is TNFSF14; the disease is kidney disorder.